EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)

Phase II trial of multi-tyrosine kinase inhibitor ESK981 in combination with PD-1 inhibitor nivolumab in patients with metastatic castration-resistant prostate cancer

Elisabeth I Heath iD, Wei Chen, Jae E Choi, Kimberlee Dobson, Melanie Smith, Tomasz Maj, Ilona Kryczek, Weiping Zou, Arul M Chinnaiyan, Yuanyuan Qiao

Investigational New Drugs · 2024

DOI: 10.1007/s10637-024-01482-8 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Investigational New Drugs, 2024. Verfasst von Elisabeth I Heath und 9 weiteren Autor:innen. Beteiligte Einrichtung: Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA. heathe@karmanos.org. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant, Nivolumab, Protein Kinase Inhibitors, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 26 Literaturangaben. Gefördert von: NCI NIH HHS, National Cancer Institute, United States, U.S. Department of Defense.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Increasing the response rates of immune checkpoint inhibitors in patients with metastatic castration-resistant prostate cancer (mCRPC) presents a significant challenge. ESK981 is a multi-tyrosine kinase and PIKfyve lipid kinase inhibitor that augments immunotherapeutic responses. In this phase II study, ESK981 was combined with the PD-1 blocking monoclonal antibody nivolumab to test for potentially improved response rates in patients with mCRPC who have progressed on androgen receptor (AR)-targeted agents and chemotherapy. Eligible patients received ESK981 orally once daily for five consecutive days, followed by a two-day break. Patients were also treated with nivolumab intravenously on Day 1 of each 28-day cycle. The primary endpoints were a 50% reduction in prostate-specific antigen (PSA50), and safety. Secondary endpoints included radiographic progression free survival (rPFS) and overall survival (OS). Additional investigations included whole exome sequencing in patients. Ten patients were enrolled. The maximum PSA decline from baseline of 14% was achieved in only one patient. Grade 3 treatment-related adverse events (AEs) included fatigue, anemia, and lymphopenia. There were no Grade 4 events. The median rPFS was 3.7 months (95% CI, 1.6-8.4). The median OS was 9.6 months (95% CI, 1.8-22.4). The study was terminated due to futility after 10 patients. Whole exome sequencing identified AR amplification in 63% of patients (5/8). ESK981 + nivolumab showed no antitumor activity in patients with AR-positive (AR+) mCRPC. Further evaluation of ESK981 combined with the PD-1 inhibitor nivolumab in AR + mCRPC patients is not warranted. (Trial registration: ClinicalTrials.gov NCT04159896. Registration date: November 12, 2019.).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic Neoplasms, Castration-ResistantNivolumabProtein Kinase InhibitorsAntineoplastic Combined Chemotherapy ProtocolsHumansMaleAgedMiddle AgedImmune Checkpoint InhibitorsAged, 80 and overProgrammed Cell Death 1 ReceptorProgression-Free SurvivalProstate-Specific AntigenTyrosine Kinase Inhibitors

Stichwörter der Autor:innen

CombinationESK981NivolumabProstate cancerTyrosine kinase inhibitor

Substanzen

NivolumabProtein Kinase InhibitorsImmune Checkpoint InhibitorsProgrammed Cell Death 1 ReceptorPDCD1 protein, humanProstate-Specific AntigenTyrosine Kinase Inhibitors

Autor:innen und Institutionen

  • Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA. heathe@karmanos.org.
  • Department of Oncology, Wayne State University School of Medicine, Detroit, MI, USA. heathe@karmanos.org.
  • Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA.
  • Department of Oncology, Wayne State University School of Medicine, Detroit, MI, USA.
  • Michigan Center for Translational Pathology, University of Michigan School of Medicine, Ann Arbor, MI, USA.
  • Department of Surgery, University of Michigan, Ann Arbor, MI, USA.

ORCID-Profile: Elisabeth I Heath

Förderung

  • NCI NIH HHS
  • National Cancer Institute, United States
  • U.S. Department of Defense
  • Esanik Therapeutics

Zitieren

APA

Heath, E. I., Chen, W., Choi, J. E., Dobson, K., Smith, M., Maj, T., Kryczek, I., Zou, W., Chinnaiyan, A. M., & Qiao, Y. (2024). Phase II trial of multi-tyrosine kinase inhibitor ESK981 in combination with PD-1 inhibitor nivolumab in patients with metastatic castration-resistant prostate cancer. Investigational New Drugs. https://doi.org/10.1007/s10637-024-01482-8

Vancouver

Heath EI, Chen W, Choi JE, Dobson K, Smith M, Maj T, et al. Phase II trial of multi-tyrosine kinase inhibitor ESK981 in combination with PD-1 inhibitor nivolumab in patients with metastatic castration-resistant prostate cancer. Investigational New Drugs. 2024. doi:10.1007/s10637-024-01482-8

BibTeX
@article{Heath2024,
  author = {Heath, Elisabeth I and Chen, Wei and Choi, Jae E and Dobson, Kimberlee and Smith, Melanie and Maj, Tomasz and Kryczek, Ilona and Zou, Weiping and Chinnaiyan, Arul M and Qiao, Yuanyuan},
  title = {Phase II trial of multi-tyrosine kinase inhibitor ESK981 in combination with PD-1 inhibitor nivolumab in patients with metastatic castration-resistant prostate cancer},
  journal = {Investigational New Drugs},
  year = {2024},
  doi = {10.1007/s10637-024-01482-8}
}
Kostenlos starten →